Drugs / AJMUC1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05812326 | May 2019 → Nov 2022 | female breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AJMUC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05812326 ↗ |
| Action | Deplete | “T cells expressing the receptor can recognize and kill MUC1 positive tumor cells” NCT05812326 ↗ |
| Modality | Cell therapy | “AJMUC1 is a genetically modified T cell therapeutic product” NCT05812326 ↗ |
| Target | MUC1 | “CAR targeting MUC1 is introduced into autologous T cells” NCT05812326 ↗ |